3 results
The objective of this study is to evaluate the dose-ranging response in safety and efficacy of R115866 0.5mg, 1mg and 2mg and R115866 placebo given once daily for the treatment of subjects with plaque psoriasis to select a dose for further clinical…
- to evaluate the FVIIa activity PK of 2 CSL689 dose levels in subjects with congenital FVII deficiency- to determine the PK characteristics of FVIIa activity of CSL689- to evaluate the safety and tolerability of intravenous administration of CSL689
Primary objective: to evaluate the disease activity after dose reduction, aiming adalimumab concentration of 2 mg/L or 5 mg/L, in rheumatoid arthritis patients responding to adalimumab.Secondary objectives: to evaluate whether reducing adalimumab…